US and UK Reach Duty-Free Pact on Prescription Drugs.
The UK and US have established a key trade agreement that will maintain no duties on UK drug exports being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has committed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This move secures that duties on these vital exports will be held at nothing for a duration of the next three years.
This agreement follows previous statements to hike import taxes on patented drug products, with increases mentioned as high as one hundred percent.
"This agreement between the Britain reinforces the global environment for cutting-edge drugs and introduces much-needed balance to American-British medicine commerce," a release noted.
Economic Significance
Pharmaceuticals constitute one of the Britain's most significant goods shipped to the America, which is clearly the biggest destination for leading UK drugmakers.
Export figures reveal that in the 12 months to the end of the third quarter, the UK sold drugs valued at billions to the US. This figure accounted for 17.4% of total UK exports in that span.
"This guarantee secures employment, boosts funding and facilitates the UK to emerge as a global hub for life sciences," a government official commented.
Key British Pledges
The deal involves several key changes from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to increase total public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum manufacturers must refund to the NHS to control costs will be capped at 15%. In the past, refunds were more than twenty percent.
Recent Tensions
This agreement comes amid a ongoing row between the drug companies and the British authorities over drug pricing and NHS adoption.
The disagreement were heightened by arguments that American consumers were paying significantly more for the identical medicines than patients in the other developed nations.
Recently, several significant drug company projects in the UK have been paused or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister acknowledged that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the previous ten-year period.
